Clinical trial
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
NCT00142116 · Steven P. Treon, MD, PhD, Other · Completed
Key facts
| NCT number | NCT00142116 |
|---|---|
| Title | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia |
| Lead sponsor | Steven P. Treon, MD, PhD, Other |
| Collaborators | Dana-Farber Cancer Institute Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital Cape Cod Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma |
| Intervention type | Drug |
| Interventions | Thalidomide, Rituximab |
| Enrollment | 25 |
| Start date | May 1, 2003 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2008 |
| First posted | Sep 2, 2005 |
| Last update posted | Jun 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: